Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s00223-021-00858-9 http://scihub22266oqcxt.onion/10.1007/s00223-021-00858-9 34003337!8129963!34003337     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Calcif+Tissue+Int 2021 ; 109 (4): 351-362 Nephropedia Template TP {{tp|p=34003337|t=2021. Diagnosis and Management of Osteoporosis During COVID-19: Systematic Review and Practical Guidance |pdf=|usr=}}{{34003337}} gab.com Text Diagnosis and Management of Osteoporosis During COVID-19: Systematic Review and Practical Guidance JO: Calcif Tissue Int http://www.kidney.de/pget.php?&tw=1&pmid=34003337 #FOAvip It is acknowledged that the COVID-19 pandemic has caused profound disruption to the delivery of healthcare services globally. This has affected the management of many long-term conditions including osteoporosis as resources are diverted to cover urgent care. Osteoporosis is a public health concern worldwide and treatment is required for the prevention of further bone loss, deterioration of skeletal micro-architecture, and fragility fractures. This review provides information on how the COVID-19 pandemic has impacted the diagnosis and management of osteoporosis. We also provide clinical recommendations on the adaptation of care pathways based on experience from five referral centres to ensure that patients with osteoporosis are still treated and to reduce the risk of fractures both for the individual patient and on a societal basis. We address the use of the FRAX tool for risk stratification and initiation of osteoporosis treatment and discuss the potential adaptations to treatment pathways in view of limitations on the availability of DXA. We focus on the issues surrounding initiation and maintenance of treatment for patients on parenteral therapies such as zoledronate, denosumab, teriparatide, and romosozumab during the pandemic. The design of these innovative care pathways for the management of patients with osteoporosis may also provide a platform for future improvement to osteoporosis services when routine clinical care resumes. Twit Text FOAVip Diagnosis and Management of Osteoporosis During COVID-19: Systematic Review and Practical Guidance ????Calcif Tissue Int http://www.kidney.de/pget.php?&tw=1&pmid=34003337 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34003337 #FOAvip English Wikipedia <ref>{{Cite pmid|34003337}}</ref> Diagnosis and Management of Osteoporosis During COVID-19: Systematic Review and Practical Guidance #MMPMID34003337 Hampson G; Stone M; Lindsay JR; Crowley RK; Ralston SH Calcif Tissue Int 2021[Oct]; 109 (4): 351-362 PMID34003337show ga It is acknowledged that the COVID-19 pandemic has caused profound disruption to the delivery of healthcare services globally. This has affected the management of many long-term conditions including osteoporosis as resources are diverted to cover urgent care. Osteoporosis is a public health concern worldwide and treatment is required for the prevention of further bone loss, deterioration of skeletal micro-architecture, and fragility fractures. This review provides information on how the COVID-19 pandemic has impacted the diagnosis and management of osteoporosis. We also provide clinical recommendations on the adaptation of care pathways based on experience from five referral centres to ensure that patients with osteoporosis are still treated and to reduce the risk of fractures both for the individual patient and on a societal basis. We address the use of the FRAX tool for risk stratification and initiation of osteoporosis treatment and discuss the potential adaptations to treatment pathways in view of limitations on the availability of DXA. We focus on the issues surrounding initiation and maintenance of treatment for patients on parenteral therapies such as zoledronate, denosumab, teriparatide, and romosozumab during the pandemic. The design of these innovative care pathways for the management of patients with osteoporosis may also provide a platform for future improvement to osteoporosis services when routine clinical care resumes. |*Bone Density Conservation Agents/therapeutic use[MESH] |*COVID-19[MESH] |*Osteoporosis/diagnosis/drug therapy[MESH] |*Osteoporotic Fractures/diagnosis/prevention & control[MESH] |Humans[MESH] |Pandemics[MESH] |SARS-CoV-2[MESH]Diagnosis and Management of Osteoporosis During COVID-19: Systematic R(epmc).pdf DeepDyve Pubget Overpricing